Head-to-head evidence
ION904 vs Zilebesiran
Same mechanism, same race: design-graded trial evidence for both assets, with the grading rationale shown. Grades describe the quality of the evidence, never the merits of either security.
Hypertension
Shared mechanism: Angiotensinogen (AGT) · full Hypertension pipeline
ION904
Developed by Ionis Pharmaceuticals
NCT05314439 · Phase 2 · completed
The study randomly assigned 48 participants to ION904 or placebo and masked participants, investigators, and outcome assessors. However, its primary endpoint was the surrogate biomarker plasma angiotensinogen, and no primary endpoint results have been posted.
Zilebesiran
Developed by Alnylam Pharmaceuticals and partners
NCT04936035 · Phase 2 · completed
The study randomized 394 participants to placebo or zilebesiran and maintained quadruple blinding, with approximately 60–75 participants per treatment group analyzed for the primary endpoint. The primary clinical endpoint—change in 24-hour ambulatory systolic blood pressure at Month 3—was significantly favorable for zilebesiran versus placebo, supporting strong evidence from this trial.
Next expected readout: April 2028 · NCT07553442 (registry estimate)
The full competitive landscape for each asset (every same-race competitor with aligned evidence, sortable) is on the asset pages: ION904's landscape · Zilebesiran's landscape